Article Sidebar

PDF
Date Published: 17/10/2022
Abstract Views: 479
Views PDF: 184
DOI: https://doi.org/10.51298/vmj.v519i1.3506
Issue
Vol. 519 No. 1 (2022)
Section
Các bài báo
How to Cite
Hữu Thắng, N. ., Thành Kiên, H. ., & Hồng Thăng, V. . (2022). EFFICACY OF CETUXIMAB COMBINED WITH CHEMOTHERAPY IN STAGE IV COLORECTAL CANCER AT K HOSPITAL. Vietnam Medical Journal, 519(1). https://doi.org/10.51298/vmj.v519i1.3506

EFFICACY OF CETUXIMAB COMBINED WITH CHEMOTHERAPY IN STAGE IV COLORECTAL CANCER AT K HOSPITAL

Nguyễn Hữu Thắng1,, Hà Thành Kiên2, Vũ Hồng Thăng2,3
1 Department of Oncology, Hanoi Medical University
2 Vietnam National Cancer Hospital
3 Department of Oncology, Hanoi Medical Universit

Main Article Content

Abstract

Background: In recent years, the epithelial growth factor receptor inhibitor Cetuximab has demonstrated its important role in the combination with chemotherapy in the treatment of RAS/BRAF wild-type stage IV colon cancer. We carried out this study to evaluate the efficacy and adverse events of the regimen at K hospital. Subjects and methods: This is a descriptive study on 40 patients diagnosed with stage IV colorectal cancer without RAS/BRAF mutations at K hospital from July 2017 to August 2022 that were treated with Cetuximab combined with chemotherapy regimens of mFOLFOX6 or mFOLFIRI. Results: Overall response rate (ORR) was 57.5%, median progression-free survival (PFS) was 12.0 months, median overall survival (OS) was 31.0 months. The most common side effects are diarrhea (60%), increased liver enzymes (50%) and acne-form dermatitis (40%), mainly in grade 1 and 2 with the rate of 55%, 47.5% and 25% respectively; no serious adverse events were noted. Conclusion: Cetuximab combined with chemotherapy resulted in high response rate, long progression-free and overall survival and was well tolerated by patients.

Article Details

Keywords

cetuximab, stage IV colorectal cancer

References

1. Li R, Liang M, Liang X, Yang L, Su M, Lai KP. Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis. Front Oncol. 2020;10. Accessed August 23, 2022. https://www.frontiersin.org/articles/10.3389/fonc.2020.00868
2. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. doi:10.1016/j.gene.2005.10.018
3. Merck KGaA, Darmstadt, Germany. Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-Line Treatment for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Cancer. clinicaltrials.gov; 2017. Accessed August 21, 2022. https://clinicaltrials.gov/ct2/show/NCT00154102
4. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol Stockh Swed. 2014;53(7):852-864. doi:10.3109/0284186X.2014.895036
5. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer Oxf Engl 1990. 2017;70:87-98. doi:10.1016/j.ejca.2016.10.007
6. Neugut AI, Lin A, Raab GT, et al. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019; 18(2):133-140. doi:10.1016/j.clcc.2019.01.005
7. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075. doi:10.1016/ S1470-2045(14)70330-4